Neal Bhatia - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Neal Bhatia's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Neal Bhatia
Verified
Contributor, Dermatology Times
California
Beats
Infectious Disease , Mental Health, Addiction , Biology, Child Health, Global Health
Content
By Rebecca Forand Verified, Carol L. DiBerardino Verified, Neal Bhatia| Healio Dermatology Verified Key takeaways: IGA success rates and lesion count reductions were higher in those treated with Emrosi vs. placebo or Oracea. Emrosi was approved by the FDA in November 2024 and launched by Journey Medical on March 24. Patients with rosacea experienced improvement with Emrosi, an oral minocycline hydrochloride extended-release product, according to results from two phase 3 clinical trials.
Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea: Two Phase 3 Randomized Clinical Trials
By Neal Bhatia, James Del Rosso, Linda Gold| JAMA (The Journal of the American Medical Association) Verified Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea: Two Phase 3 Randomized Clinical Trials Key PointsQuestion What is the efficacy and safety of DFD-29, 40 mg, a low-dose oral minocycline hydrochloride formulation, in moderate to severe rosacea compared with doxycycline, 40 mg, and placebo?
By Rebecca Forand Verified, Carol L. DiBerardino Verified, Neal Bhatia| Healio Dermatology Verified Key takeaways: IGA success rates and lesion count reductions were higher in those treated with Emrosi vs. placebo or Oracea. Emrosi was approved by the FDA in November 2024 and launched by Journey Medical on March 24. Patients with rosacea experienced improvement with Emrosi, an oral minocycline hydrochloride extended-release product, according to results from two phase 3 clinical trials.
Company Info
Dermatology Times
Dermatology Times is a prominent news resource and weekly newsmagazine dedicated to dermatologists and skin care professionals. Based in Cranbury, US, with operations in North Olmsted, Ohio, the company provides timely clinical insights, regulatory news, and practice management strategies. It covers the latest developments in dermatology, including breakthrough treatments and emerging trends. The company also hosts educational events and conferences, such as the "Revolutionizing Atopic Dermatitis (RAD) Conference" and the "Cases and Conversations" series, focusing on various dermatological conditions. Additionally, Dermatology Times features a weekly crossword puzzle that combines dermatology knowledge with entertainment, helping professionals reinforce their expertise. With a readership of over 16,000 dermatologists and skin care professionals, Dermatology Times plays a vital role in keeping practitioners informed and engaged in their field.
'+1 609-716-7777
Founded: 1979